ArticleJournal of nanobiotechnology2026
Healthy young human plasma-derived exosomes enhance neural stem cell therapy by suppressing pyroptosis via TXNIP/NLRP3 after intracerebral hemorrhage.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MSC-derived exosomes for hemorrhagic stroke: preclinical evidence and translational challenges.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundNeural stem cells (NSCs) transplantation holds promise for intracerebral hemorrhage (ICH) treatment, but its efficacy is limited by poor survival and aberrant differentiation of grafted cells. Here, we demonstrate that exosomes derived from healthy young donor plasma, a natural nanomaterial protect NSCs against pyroptosis, a gasdermin-dependent inflammatory cell death process triggered by ICH.
methodsPlasma exosomes were extracted from young (Y-exo) and old (O-exo) healthy individuals and characterized. An in vitro model of ICH was established by hemin treatment. For the in vivo study, the mouse ICH model was induced by autologous blood, a combined transplantation of Y-exo and NSCs was then performed as the therapeutic intervention. The protective effects of exosomes on NSCs were assessed via western blotting, immunofluorescence, ELISA, qPCR, and Calcein/PI detection. The therapeutic effects of combined transplantation of Y-exo and NSCs on ICH mice were evaluated through in vivo imaging systems and a series of behavioral tests.
resultsExosomes derived from young plasma exert protective effects by supporting NSC survival, boosting their proliferative and differentiation capacity in vitro, and ameliorating the peri-hematoma microenvironment in vivo. Strikingly, the efficacy of Y-exo is superior to that of O-exo. Subsequent studies will use Y-exo, in vitro, the Y-exo exerted their protective effects by inhibiting the NLRP3/Caspase-1/GSDMD-mediated pyroptotic pathway and reducing the release of inflammatory cytokines. In vivo, co-transplantation of NSCs and Y-exo enhanced NSCs survival, proliferation, and beneficial differentiation toward neuronal and oliodendroglial lineage while attenuating pyroptosis of NSCs and peri-hematoma tissue. Behavioral tests indicated that mice in the co-transplantation group exhibited superior functional recovery. MiRNA sequencing identified miR-16-5p as a key mediator enriched in Y-exo, which targeted TXNIP to disrupt NLRP3 inflammasome activation. Genetic and pharmacological interventions confirmed that miR-16-5p/TXNIP/NLRP3 signaling pathway is essential for Y-exo's anti-pyroptotic effects.
conclusionsOur study elucidates a previously unidentified mechanism whereby Y-exo improve neurological outcomes by alleviating the peri-hematoma inflammatory microenvironment, suppressing pyroptosis in transplanted stem cells, and altering their differentiation fate. This study highlights the potential of synergistic strategy to optimize NSCs-based therapy for stroke by combining youth-derived factors, offering new insights into regenerative therapeutics for neurological disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.